| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 07/19/2007 | WO2007081729A2 Treatment modalities for autoimmune diseases |
| 07/19/2007 | WO2007081710A2 Treatment modalities for autoimmune diseases |
| 07/19/2007 | WO2007081696A2 Treating androgen decline in aging male (adam)-associated conditions with sarms |
| 07/19/2007 | WO2007081694A2 Derivatives of sulindac, use thereof and preparation thereof |
| 07/19/2007 | WO2007081690A2 Inhibitors of protein kinases |
| 07/19/2007 | WO2007081630A2 Substituted pyrimidinyl kinase inhibitors |
| 07/19/2007 | WO2007081572A2 Inhibitors of checkpoint kinases |
| 07/19/2007 | WO2007081571A2 Cetp inhibitors |
| 07/19/2007 | WO2007081570A2 Cholesteryl ester transfer protein inhibitors |
| 07/19/2007 | WO2007081569A2 Cetp inhibitors |
| 07/19/2007 | WO2007081560A2 Amino acid derivatives of indolinone based protein kinase inhibitors |
| 07/19/2007 | WO2007081542A2 Tetralone-based monoamine reuptake inhibitors |
| 07/19/2007 | WO2007081540A2 Tylophorine analogs as antitumor agents |
| 07/19/2007 | WO2007081521A2 Salts of potassium atp channel openers and uses thereof |
| 07/19/2007 | WO2007081419A2 Compositions and methods related to anti-fgf agents |
| 07/19/2007 | WO2007081404A1 Skin disinfectant composition and methods for using |
| 07/19/2007 | WO2007081374A1 Serotonergic agents for treating sexual dysfunction |
| 07/19/2007 | WO2007081367A1 Dry formulations of aripiprazole |
| 07/19/2007 | WO2007081366A1 Wet granulation pharmaceutical compositions of aripiprazole |
| 07/19/2007 | WO2007081341A1 Controlled release formulation of divalproic acid and its derivatives |
| 07/19/2007 | WO2007081335A1 Therapeutic compounds for treating dyslipidemic conditions |
| 07/19/2007 | WO2007081235A1 Method for treating oncological diseases |
| 07/19/2007 | WO2007081232A1 Drug combinations |
| 07/19/2007 | WO2007081206A1 A method of treating an acute vascular disorder |
| 07/19/2007 | WO2007081190A1 Novel use of 1,2,3,4,6-penta-o-galloyl-beta-d-glucose |
| 07/19/2007 | WO2007081115A1 Composition comprising liquiritigenin for preventing and treating liver disease |
| 07/19/2007 | WO2007081091A1 Rhodandse derivarives, a process for the preparation thereof and pharmaceutical composition containing the same |
| 07/19/2007 | WO2007081061A1 Therapeutic agent for neurogenic pain |
| 07/19/2007 | WO2007081060A1 Therapeutic agent for neuropathic pain |
| 07/19/2007 | WO2007081031A1 Glycosyltransferase inhibitor |
| 07/19/2007 | WO2007081030A1 Pyrrolopyridazinone compound |
| 07/19/2007 | WO2007080977A1 Preventive or therapeutic agent and method for immune disease |
| 07/19/2007 | WO2007080965A1 Anti-allergic agent and beverage/food, preparation for external application or cosmetic comprising the agent |
| 07/19/2007 | WO2007080902A1 Composition inhibiting the expression of target gene in eyeball and remedy for disease in eyeball |
| 07/19/2007 | WO2007080885A1 Cycloalkanecarboxamide derivative and method for producing same |
| 07/19/2007 | WO2007080882A1 Oxazolone derivative |
| 07/19/2007 | WO2007080787A1 Coenzyme q10-containing water-soluble compositions |
| 07/19/2007 | WO2007080776A1 Sustained release preparation and method for production thereof |
| 07/19/2007 | WO2007080721A1 Therapeutic agent for lewy body disease and prophylactic agent for lewy body disease |
| 07/19/2007 | WO2007080669A1 Antiviral/antiinflammatory drug composition |
| 07/19/2007 | WO2007080659A1 AGENT FOR INCREASING BONE MINERAL CONTENT COMPRISING p-HYDROXYCINNAMIC ACID AS ACTIVE INGREDIENT |
| 07/19/2007 | WO2007080630A1 AGENT FOR INCREASING BONE MINERAL CONTENT COMPRISING p-HYDROXYCINNAMIC ACID AS ACTIVE INGREDIENT |
| 07/19/2007 | WO2007080601A1 Stable pharmaceutical formulation of an acid labile compound and process for preparing the same |
| 07/19/2007 | WO2007080598A2 A pharmaceutical composition for inhibiting/reducing neointimal proliferation and restenosis. |
| 07/19/2007 | WO2007080595A2 Electrode assemblies, tools, and methods for gastric wall implantation |
| 07/19/2007 | WO2007080560A2 The use of the process of induction of de novo synthesis of p-glycoprotein (p-gp) in the treatment of xenobiotic-induced intoxications in mammals |
| 07/19/2007 | WO2007080542A1 Novel thiophene derivatives as s1p1/edg1 receptor agonists |
| 07/19/2007 | WO2007080509A2 Sustained release compositions of alfuzosin |
| 07/19/2007 | WO2007080507A2 Processes for the preparation of azithromycin |
| 07/19/2007 | WO2007080401A1 Triazoloanilinopyrimidine derivatives for use as antiviral agents |
| 07/19/2007 | WO2007080378A1 Use of morpholino compounds for the treatment of halitosis |
| 07/19/2007 | WO2007080362A1 Pharmaceutically acceptable co-crystalline forms of sildenafil |
| 07/19/2007 | WO2007080325A1 Fgf-receptor agonist dimeric compounds |
| 07/19/2007 | WO2007080324A2 Pyridopyrimidone derivatives, preparation thereof, therapeutic use thereof |
| 07/19/2007 | WO2007080321A1 Method for the manufacture of a pharmaceutical form of oseltamivir phosphate |
| 07/19/2007 | WO2007080270A2 New cholest-4-en-3-one oxime derivatives, pharmaceutical compositions comprising them, and preparation process |
| 07/19/2007 | WO2007080263A1 Pharmaceutical composition containing omega-3 fatty acids and a silica |
| 07/19/2007 | WO2007080203A1 Gene construct, vector and dna vaccine for the vaccination of aquatic animals |
| 07/19/2007 | WO2007080191A1 6-phenyl-1h-imidazo[4, 5-c]pyridine-4-carbonitrile derivatives as cathepsin k and s inhibitors |
| 07/19/2007 | WO2007080170A1 CRYSTALLINE FORM OF 1´-(1-METHYLETHYL)- 4´-[(2-FLUORO-4-METHOXYPHENYL)METHYL]-5´-METHYL-1H-PYRAZOL-3´-O-β-D-GLUCOPYRANOSIDE, A METHOD FOR ITS PREPARATION AND THE USE THEREOF FOR PREPARING MEDICAMENTS |
| 07/19/2007 | WO2007080149A2 Treatment of stressed patients |
| 07/19/2007 | WO2007080140A1 Cyclohexyl piperazinyl methanone derivatives and their use as histamine h3 receptor modulators |
| 07/19/2007 | WO2007080124A1 Combination of mtor inhibitor and antipolate compound |
| 07/19/2007 | WO2007080116A2 Use of cns penetrating anticancer compounds for the treatment of protozan diseases |
| 07/19/2007 | WO2007080109A1 Substituded benzyloxy-phenylmethylurea derivatives |
| 07/19/2007 | WO2007080108A1 Composition ascorbic acid and a metal ion for selective killing of pathological mammalian cells |
| 07/19/2007 | WO2007080074A1 Solid pharmaceutical composition comprising irbesartan |
| 07/19/2007 | WO2007080010A1 Oral s-adenosylmethionine compositions |
| 07/19/2007 | WO2007079982A1 (2 , 4 , 9-triaza-1 (2 , 4 ) -pyrimidina-3 ( 1 , 3 ) -benzenacyclononaphane-3 4-yl) -sulfoximine derivatives as selective aurora kinase inhibitors for the treatment of cancer |
| 07/19/2007 | WO2007079970A1 Novel use of a nutraceutical composition in animal feed |
| 07/19/2007 | WO2007079961A1 Substituted thiazoles and their use for producing drugs |
| 07/19/2007 | WO2007079960A1 Substituted thiazoles and their use for producing drugs |
| 07/19/2007 | WO2007079959A1 Substituted propiolic acid amides and their use for producing analgesics |
| 07/19/2007 | WO2007079957A1 Substituted propiolic acid amides and their use for producing drugs |
| 07/19/2007 | WO2007079931A1 Substituted oxadiazole derivatives and their use as opioid receptor ligands |
| 07/19/2007 | WO2007079928A1 Substituted oxazole derivatives with an analgesic action |
| 07/19/2007 | WO2007079927A1 Substituted imidazoline derivatives |
| 07/19/2007 | WO2007079918A1 COMBINATION OF TRIAZINE DERIVATIVES AND PPARα AGONISTS |
| 07/19/2007 | WO2007079917A2 Combination of triazine derivatives and insulin sensitisers |
| 07/19/2007 | WO2007079916A2 Combination of triazine derivatives and hmg- coa reductase inhibitors for the treatment of diabetes |
| 07/19/2007 | WO2007079915A2 Use of triazine derivatives for the manufacture of a medicament having a cicatrising or angiogenic effect |
| 07/19/2007 | WO2007079914A2 Combination of triazine derivatives and insulin secretion stimulators |
| 07/19/2007 | WO2007079902A1 Derivatives of 2-nitro-1,3-imidazole coupled to amino acids and deoxyribose useful for the detection of hypoxic biological tissue |
| 07/19/2007 | WO2007079862A1 Novel, acyclic substituted furopyrimidine derivatives and use thereof for treating cardiovascular diseases |
| 07/19/2007 | WO2007079861A1 Novel, cyclic substituted furopyrimidine derivatives and use thereof for treating cardiovascular diseases |
| 07/19/2007 | WO2007079842A1 Benzochromene derivatives for use in liquid crystal media and as therapeutic active substances |
| 07/19/2007 | WO2007079840A2 Benzochromene derivatives |
| 07/19/2007 | WO2007079826A1 Diazepinones |
| 07/19/2007 | WO2007079820A1 Triazole derivatives |
| 07/19/2007 | WO2007079681A1 Pyrazole carboxamide derivatives, pharmaceutical compositions and its preparation |
| 07/19/2007 | WO2007079653A1 OPTICALLY PURE α-SUBSTITUTED 2-METHYL-5-NITROIMIDAZOLE-1-ETHANOL DERIVATIVES |
| 07/19/2007 | WO2007079560A2 Pharmaceutical compounds that contain nanoparticles useful for treating restenotic lesions |
| 07/19/2007 | WO2007079515A1 Mutilin derivatives and their use as pharmaceutical |
| 07/19/2007 | WO2007064931A3 Substituted 4-amino-pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis |
| 07/19/2007 | WO2007064664A3 Prostaglandin ep4 agonists for the treatment of gastric conditions |
| 07/19/2007 | WO2007064397A3 Synergistic binder composition, method for making same, and tablets of an active and said binder having advantageous hardness and friability |
| 07/19/2007 | WO2007062837A3 Use of a 5-ht4 agonist for the treatment of irritable bowel syndrome characterized by mixed or alternating bowel habits |
| 07/19/2007 | WO2007062462A8 Method for administering a skin necrosis composition to an animal |
| 07/19/2007 | WO2007061828A3 Pharmaceutical compositions comprising buprenorphine |
| 07/19/2007 | WO2007059613B1 Antineoplastic compounds |